The Potential of Antiviral Peptides as COVID-19 Therapeutics

  title={The Potential of Antiviral Peptides as COVID-19 Therapeutics},
  author={Aravindh Mahendran and Yin Sze Lim and Chee-Mun Fang and Hwei-San Loh and Cheng Foh Le},
  journal={Frontiers in Pharmacology},
To date, more than 17 million cases of coronavirus disease 2019 (COVID-19) and 900,000 deaths have been reported globally (World Health Organization, 2020). Major collaborative efforts focusing on the development of anti-SARS-CoV-2 vaccines and antiviral therapeutics are accelerated at an unprecedented rate. Various therapeutic agents quickly taken into clinical trials are largely based on existing drugs with non-specific antiviral activities or compounds pharmacologically speculated to be… 

Figures from this paper

Antimicrobial peptides: A plausible approach for COVID-19 treatment
This review critically discusses various types of AVPs evaluated for the treatment of COVID-19 along with their mechanisms of action and anticipates them to be blockbuster drugs for the management of this serious infection.
Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2
Evidence supporting the efficacy of antiviral AMPs is summarized and their potential to treat emerging viral diseases including COVID-19 is discussed.
Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2
It is demonstrated that brilacidin, a synthetic small molecule with peptide-like properties, is capable of exerting potent in vitro antiviral activity against SARS-CoV-2, both as a standalone treatment and in combination with remdesivir, which is currently the only FDA-approved drug for the treatment of COVID-19.
Gramicidin S and melittin: potential anti-viral therapeutic peptides to treat SARS-CoV-2 infection
The in vitro antiviral assay results showed significant decrease in the viral load compared to the untreated group with no/very less cytotoxicity and more than 250 proteins were found to be differentially regulated in the gramicidin S and melittin treated SARS-CoV-2 infected Vero cells.
Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture
The data suggest that SARS-CoV-2 inhibition in these cell culture models is likely to be a result of the impact of brilacidin on viral entry and its disruption of viral integrity.
SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies
The data indicate that S protein subunits and their variable conformational states significantly affect the virus pathogenesis, infectivity, and evolutionary mutation, leading to a significant reduction of the global health burden of this pandemic.
Tripeptides from Allium subhirsitum L. extracts: Pharmacokinetics properties, toxicity prediction and in silico study against SARS-CoV-2 enzymes and pro-inflammatory proteins.
Results from pharmacophore, drug-likeness and ADMET prediction analyses clearly evidenced the usability of the peptides to be developed as an effective drug, beneficial for COVID-19 treatment.
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update
An overview of the virus interaction with the host and environment and anti-CoV therapeutic strategies; including vaccines and other methodologies, designed for prophylaxis and treatment of SARS- coV-2 infection are presented with the hope that this integrative analysis could help develop novel therapeutic approaches against COVID-19.


Antiviral peptides as promising therapeutic drugs
This review aims to shed some light on antimicrobial peptides with antiviral activities against human viruses and update the data about the already well-known peptides that are still undergoing studies, emphasizing the most promising ones that may become medicines for clinical use.
Human Antimicrobial Peptides as Therapeutics for Viral Infections
Recent studies elucidating the efficacy and diverse mechanisms of action of various classes of AMPs against multiple viral pathogens, as well as the potential use of human AMPs in novel antiviral therapeutic strategies are summarized.
Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.
SARS-CoV-2 invades host cells via a novel route: CD147-spike protein
The discovery of the new route CD147-SP for SARS-CoV-2 invading host cells provides a critical target for development of specific antiviral drugs.
Perspective of Use of Antiviral Peptides against Influenza Virus
The therapeutic properties of peptides used in influenza treatment are discussed, with a review of the current literature describing the antiviral activity, mechanism and future therapeutic potential of these influenza antiviral peptides.
Design and Evaluation of Sifuvirtide, a Novel HIV-1 Fusion Inhibitor*
Sifuvirtide has potential to become an ideal fusion inhibitor for treatment of HIV/AIDS patients, including those with HIV-1 strains resistant to T20, as well as the results from Phase Ia clinical studies, which suggest that sifuvIRTide has a different mechanism of action from that of T20.
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
EK1C4 was the most potent fusion inhibitor against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection with IC50s of 1.3 and 15.8 nM, about 241- and 149-fold more potent than the original EK1 peptide, respectively.
Sifuvirtide, a potent HIV fusion inhibitor peptide.